Institution · ProteoTech (United States)

Most cited papers from ProteoTech (United States)

ProteoTech (United States)

What are the most cited papers from ProteoTech (United States)?

The most cited paper from ProteoTech (United States) is "The Amazon rain forest plant Uncaria tomentosa (cat’s claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles" (Alan D. Snow, Gerardo M. Castillo, Beth P. Nguyen et al., 2019), with 72 citations. Next come "Laminin inhibition of ?-amyloid protein (A?) fibrillogenesis and identification of an A? binding site localized to the globular domain repeats on the laminin a chain" (61) and "P3‐254: Exebryl‐1: A novel small molecule currently in human clinical trials as a disease‐modifying drug for the treatment of Alzheimer's disease" (19).

Published TypeFieldAccess

Showing 14 of 14 papers. Every paper is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	The Amazon rain forest plant Uncaria tomentosa (cat’s claw) and its specific proanthocyanidin constituents are potent inhibitors and reducers of both brain plaques and tangles Alan D. Snow, Gerardo M. Castillo, Beth P. Nguyen et al. · Scientific Reports Open access	6 Feb 2019	72
2	Laminin inhibition of ?-amyloid protein (A?) fibrillogenesis and identification of an A? binding site localized to the globular domain repeats on the laminin a chain Gerardo M. Castillo, Widia Lukito, Elaine R. Peskind et al. · Journal of Neuroscience Research	2000	61
3	P3‐254: Exebryl‐1: A novel small molecule currently in human clinical trials as a disease‐modifying drug for the treatment of Alzheimer's disease Alan D. Snow, Joel A. Cummings, Thomas P. Lake et al. · Alzheimer s & Dementia	25 Jun 2009	19
4	P2‐529: Identification of Exebryl‐1® and other novel small molecules as tau protein aggregation inhibitors Qubai Hu, Judy A. Cam, Thomas P. Lake et al. · Alzheimer s & Dementia	Jul 2011	5
5	Measuring APP Carboxy-Terminal Fragments Luke Esposito · Methods in molecular biology Book chapter	2010	4
6	P4–319: Development of exebryl–1: A disease modifying small molecule therapeutic that causes a marked clearance of brain amyloid load and improved memory in transgenic mouse models of Alzheimer's disease Alan D. Snow, Joel A. Cummings, Thomas P. Lake et al. · Alzheimer s & Dementia Open access	Jul 2006	3
7	Electron microscopy and X-ray diffraction studies further confirm the efficacy of PTI-000703™ (Cat's claw derivative) as a potent inhibitor of Alzheimer's beta-amyloid protein fibrillogenesis Gerardo M. Castillo, Daniel A. Kirschner, Ann G. Yee et al. · Neurobiology of Aging	May 2000	2
8	P2‐310: Exebryl‐1: A novel small‐molecule drug that markedly reduces amyloid plaque load and improves memory, enters human clinical trials Alan D. Snow, Joel A. Cummings, Thomas P. Lake et al. · Alzheimer s & Dementia	Jul 2008	2
9	P4–320: Development of novel disease–modifying small peptides that cause a reduction of brain amyloid plaque load and improved memory in a transgenic mouse model of Alzheimer's disease Alan D. Snow, Joel A. Cummings, Thomas P. Lake et al. · Alzheimer s & Dementia	Jul 2006	1
10	P2‐311: Blood‐brain barrier penetration of a novel disease‐modifying 7‐mer peptide (DP‐74) that reduces brain amyloid plaque load and improves memory in a transgenic mouse model of Alzheimer's disease Alan D. Snow, Joel A. Cummings, Thomas P. Lake et al. · Alzheimer s & Dementia	Jul 2008	1
11	P4–082: Heparan sulfate proteoglycan accumulation occurs concurrent with beta–amyloid protein plaque deposition in APP transgenic mouse models of Alzheimer's disease Joel A. Cummings, Eliezer Masliah, Edward M. Rockenstein et al. · Alzheimer s & Dementia	Jul 2006	0
12	O4‐11‐04: Identification of novel small molecules as tau protein aggregation inhibitors Judy A. Cam, Joel A. Cummings, Thomas P. Lake et al. · Alzheimer s & Dementia	Jul 2012	0
13	P4‐214: IDENTIFICATION OF NOVEL SMALL‐MOLECULE TAU AGGREGATION INHIBITORS FOR TREATMENT OF TAUOPATHIES Qubai Hu, Judy A. Cam, Kelsey Hanson et al. · Alzheimer s & Dementia	Jul 2014	0
14	Targeting α-Synuclein as a Parkinson’s Disease Therapeutic Luke Esposito · Topics in medicinal chemistry Book chapter	2014	0

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.